1301767-95-2

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1301768-08-0 (4R)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutyl]-4-methyl-2,3,4,5-tetrahydro-1H-1λ6,2-benzothiazepine-1,1-dione 
• 2905-25-1 o-bromobenzenesulfonyl chloride 
• 1301767-83-8 2-{[(4S,5R)-4-benzyl-2-oxo-1,3-oxazolidin-5-yl]methyl}-2,3,4,5-tetrahydro-1H-1 λ6,2-benzothiazepine-1,1-dione 
• 1301768-06-8 2-bromo-N-(2-methylallyl)benzenesulfonamide 
• 1301768-07-9 4-methyl-2,3,4,5-tetrahydro-1H-1λ6,2-benzothiazepine-1,1-dione 

Relevant academic research and scientific papers

HUMAN IMMUNODEFICIENCY VIRUS PROTEASE INHIBITORS

The described invention relates to novel human immunodeficiency virus protease inhibitors, pharmaceutical compositions containing at least one such inhibitor, methods of preparing such inhibitors, and methods of utilizing such inhibitors to treat HIV and

Design, synthesis, and X-ray crystallographic analysis of a novel class of Hiv-1 protease inhibitors

In the present paper, design, synthesis, X-ray crystallographic analysis, and HIV-1 protease inhibitory activities of a novel class of compounds are disclosed. Compounds 28-30, 32, 35, and 40 were synthesized and found to be inhibitors of the HIV-1 protease. The crucial step in their synthesis involved an unusual endo radical cyclization process. Absolute stereochemistry of the three asymmetric centers in the above compounds have been established to be (4S,2′R,3′S) for optimal potency. X-ray crystallographic analysis has been used to determine the binding mode of the inhibitors to the HIV-1 protease.